[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

621.P1.26 Hodgkin's Lymphoma - Biology, excluding Therapy Poster I

Oral and Poster Abstracts
Poster Session
Saturday, December 5, 2009: 5:30 PM-7:30 PM
Hall E (Ernest N. Morial Convention Center)
Prognostic Role of  PET-FDG Before Autologous Stem Cell Transplantation in Advanced Hodgkin’s Lymphoma

Alessandro Pulsoni, MD1*, Elena Cavalieri2*, Saveria Capria3*, Fabio Torelli2*, Giorgia Annechini2*, Federico De Angelis1*, Angela Matturro2*, Livia Santini2*, Giovanna Meloni4* and Robin Foà5

1Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma, Italy
2Dipartimento Biotecnologie Cellulari ed Ematologia, Universita' La Sapienza, Roma, Italy
3Cellular Biotechnologies and Hematology, Sapienza University of Rome, Roma, Italy
4Division of Hematology, Department of Cellular Biotechnologies and Hematology, “Sapienza” University, Rome, Italy
5Division of Hematology, Department of Cellular Biotechnologies and Hematology, 'Sapienza' University, Rome, Italy

Cytotoxic Molecule (CM)-Positive Classical Hodgkin Lymphoma: a Clinicopathologic Study in Comparison with Nodal Peripheral T-Cell Lymphoma of Not Otherwise Specified Type Possessing CM Expression

Naoko Asano, MD, PhD1*, Jun-Ichi Tamaru, MD, PhD2*, Fumihiro Ishida, MD, PhD3*, Tadashi Yoshino, MD, PhD4*, Yoshitoyo Kagami, MD, PhD5, Yasuo Morishima, MD, PhD5*, Masao Seto, MD, PhD6, Tomohiro Kinoshita, MD, PhD7 and Shigeo Nakamura, MD, PhD8

1Dept. of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan
2Dept. of Pathology, Saitama Medical Center, Kawagoe, Japan
3Second Dept. of Int. Med., Shinshu University, Matsumoto, Japan
4Department of Pathology, Okayama University Graduate School of Medicine, Okayama, Japan
5Dept. of Hematology and Cell Therapy, Aichi Cancer Center Hosp., Nagoya, Japan
6Div. of Molecular Med., Aichi Cancer Ctr., Nagoya, Japan
7Dept. of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
8Dept. of Pathology & Clin. Labs., Nagoya Univ. Hospital

Hodgkin Variant of Richter's Syndrome : Report of 34 Cases. A Role of EBV in Transformation ?

Bénédicte Deau, MD1*, Caroline Bonmati, MD2*, Emmanuel Bachy, MD1*, Xavier Carles, MD3*, Pauline Brice, MD4*, Franck Morschhauser, MD5*, Philippe Rousselot, MD, PhD6*, Marie-Olivia Chandesris, MD1*, Richard Delarue, MD7*, Bruno Varet, MD7*, Vincent Ribrag, MD8 and Olivier Hermine, MD, PhD7*

1Hematology, Necker Hospital, Paris, France
2Hematology, CHU Nancy, Nancy, France
3Hematology, Purpan Hospital, Toulouse, France
4Hematology, Saint Louis hospital, Paris, France
5Hematology, Centre Hospitalier Universitaire, Lille, France
6Hôpital André Mignot, Versailles, France
7Hopital Necker, Paris, France
8Dpt. of Medicine, Institut Gustave Roussy, Villejuif, France

The HGF/c-Met Signaling Pathway in Hodgkin Lymphoma

Chuanhui Xu1*, Anke Van Den Berg, PhD1*, Arjan Diepstra1*, Miao Wang2*, Debora Jong1*, Hans JTWM Vos1*, Peter Moller, MD3, Sibrand Poppema, MD, PhD1 and Lydia Visser1*

1Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands
2Pathology, Capital Medical University, Beijing, China
3Ulm University Inst. Pathology, Ulm, Germany

For Standard and High-Risk Patients with Hodgkin Lymphoma Six Cycles of Tailored BEACOPP, Based On Interim Scintigraphy, Are Effective and Female Fertility Is Preserved

Eldad Dann, MD1, Rachel Bar-Shalom, MD2*, Ada Tamir, PhD3*, Menachem Ben-Shachar, MD4*, Irit Avivi, MD1*, Tsila Zuckerman, MD1*, Nuhad Haddad, MD5*, Hanna Rosenbaum, MD1, Riva Fineman, MD5*, Odelia Goor, MD6*, Diana Libster, MD7, Zeev Blumenfeld, MD8*, Jacob M. Rowe, MD1 and Ron Epelbaum, MD9*

1Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
2Department of Nuclear Medicine, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
3Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
4Department of Oncology, Rambam Medical Center, Haifa, Israel
5Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel
6Hematology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
7Hematology Unit, Hadassah University Hospital, Jerusalem, Israel
8Gynecology, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
9Department of Oncology, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

Improved Patient Survival and Cure for Hodgkin Lymphoma: A Population-Based Study of 6,136 Patients Diagnosed in Sweden 1973-2005

Jan Sjoberg, MD, PhD1*, Cat Halthur2*, Sigurdur Y Kristinsson, M.D., Ph.D.1, Ola Landgren, M.D., Ph.D.3, Paul W Dickman2* and Magnus Bjorkholm, MD, PhD1

1Department of Medicine, Division of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden
2Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
3Medical Oncology Branch, National Cancer Institute, NIH, Bethesda, MD

The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era

Alden A. Moccia1*, Jane Donaldson1*, Mukesh Chhanabhai2, Paul Hoskins1*, Richard Klasa1, Kerry J. Savage1, Tamara Shenkier1*, Brian Skinnider2*, Randy D. Gascoyne2, Joseph M. Connors1 and Laurie H. Sehn1

1Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
2Department of Pathology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada

Chemo- and Radiotherapy Induce Common Apoptotic Mediators in Hodgkin’s Lymphoma

Raffaele Frazzi1*, Davide Nicoli2*, Mauro Iori3* and Francesco Merli1*

1Hematology, A.O. S.Maria Nuova, Reggio Emilia, Italy
2Molecular biology laboratory, A.O. S.Maria Nuova, Reggio Emilia, Italy
3Medical Physics, A.O. S.Maria Nuova, Reggio Emilia, Italy

Reproducibility of International Harmonization Project (IHP)-Based Interpretations of Posttherapy PET/CT in Patients with Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma

Malik E. Juweid, MD*, Damita Thomas, MD*, Kevin Berbaum*, David Bushnell* and Michael M Graham*

Dept. of Radiology/Nuclear Med., Univ. of Iowa College of Med., Iowa City, IA

TARC Is Useful as Additional Prognostic Factor for Hodgkin's Lymphoma Outcome

Simonetta Viviani, MD1*, Arabella Mazzocchi2*, Valeria Bonfante3*, Rosalba Miceli, MD4*, Davide Dalu, MD1*, Marina Galbiati2*, Fernando Ravagnani2*, Luigi Mariani5* and Alessandro Massimo Gianni, Director6*

1Medical Oncology, IRCCS Foundation,National Cancer Institute, Milan, Italy
2Experimental Oncology, IRCCS Foundation,National Cancer Institute, Milan, Italy
3IRCCS Foundation,National Cancer Institute, Milan, Italy
4Statistical Medicine Department, IRCCS Foundation,National Cancer Institute, Milan, Italy
5Medical Statistic and Biometry Unit, IRCCS Foundation, National Cancer Institute, Milan, Italy
6Medical Oncology, IRCCS Foundation, National Cancer Institute, Milan, Italy

Impact of Routine Surveillance Imaging on the Outcome of Patients with Relapsed Hodgkin Lymphoma

Paul A. Basciano, MD1*, Craig Moskowitz, MD2 and Andrew D. Zelenetz, MD, PhD2*

1Division of Hematology/Oncology, New York Presbyterian Hospital-Weil Cornell, New York, NY
2Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

A Study of Immune Deficiency as Risk Factor of Hodgkin's Lymphoma in Children

Leila Hamdi1*, Rita Creidy Jr.2*, Patricia Rince3*, Karim Abbed4*, Jacqueline Clavel5*, Martine Raphael Sr.6*, Judith Landman-Parker7 and Caroline Besson, MD8*

1INSERM U802, Kremlin-Bicêtre
2Hematology and Immunology, Le Kremlin Bicêtre, France
3University Paris Sud 11, Le Kremlin Bicetre, Gambia
4CHU Bicetre, Le Kremlin Bicêtre, France
5INSERM, Le Kremlin Bicetre, France
6University Paris Sud 11, Le Kremlin Bicetre, France
7Dept. of Hem./Onc./Pediatrics, Hopital Trousseau/UPMC-Paris6, Paris, France
8Hematology, Hôpital Bicêtre, Paris, France

Expression of COX-2 Is An Independent Unfavourable Prognostic Factor in Hodgkin Lymphoma Treated with ABVD with or without Radiotherapy

Francisco Mestre1*, Antonio Gutierrez, MD2, Rafael Ramos3*, Jordi Martinez-Serra2*, Antonia Bautista2*, José Fuster4*, Pilar Lopez-Marti5*, Marta Casasus1*, Cristina Nicolau1*, Julio Rifa6*, Juan Besalduch, MD7, Juan Fernando Garcia8* and Jose Rodriguez9*

1Radiotherapy, University Hospital Son Dureta, Palma, Spain
2Dept. of Hematology, Hospital Universitario Son Dureta, Palma, Spain
3Pathology, University Hospital Son Dureta
4Dept. of Oncology, Palma
5General University Hospital Gregorio Marañon, Madrid
6Oncology, University Hospital Son Dureta
7Hematology, Hospital Son Dureta, Palma de Mallorca, Spain
8CNIO
9Oncology, University Hospital Gregorio Marañon

Vascular Endothelial Growth Factor (VEGF) Expression by Neoplastic Hodgkin-Reed-Sternberg Cells Is An Independent Adverse Prognostic Factor for Relapse in Hodgkin Lymphoma

Antonio Gutierrez, MD1, Francisco Mestre2*, Rafael Ramos3*, Jordi Martinez-Serra1*, Antonia Bautista1*, José Fuster4*, Pilar Lopez-Marti5*, Marta Casasus6*, Cristina Nicolau6*, Julio Rifa7*, Joan Besalduch8*, Juan Fernando Garcia9* and Jose Rodriguez10*

1Dept. of Hematology, Hospital Universitario Son Dureta, Palma, Spain
2Nuclear Medicine, University Hospital Son Dureta, Palma, Spain
3Pathology, University Hospital Son Dureta
4Dept. of Oncology, Palma
5General University Hospital Gregorio Marañon, Madrid
6Radiotherapy, University Hospital Son Dureta, Palma, Spain
7Oncology, University Hospital Son Dureta
8Hematology, H. Son Dureta, Palma de Mallorca, Spain
9CNIO
10Oncology, University Hospital Gregorio Marañon

The Histone Deacetylase (HDAC) Inhibitor Entinostat (SNDX-275) Targets Hodgkin Lymphoma through a Dual Mechanism of Immune Modulation and Apoptosis Induction

Noor M Khaskhely, MD, PhD1*, Daniela Buglio, MD2, Jessica Shafer, MD3*, Catherine M. Bollard, MD, FRACP, FRCPA4 and Anas Younes, MD5

1Lymphoma, MD Anderson Cancer Center, Houston, TX
2Lymphoma/Myeloma, M.D. Anderson Cancer Center, Houston, TX
3Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
4Baylor College of Medicine, The Methodist Hospital, and Texas Children's Hospital, Houston, TX
5Department of Lymphoma/Myeloma, University of Texas-M.D. Anderson Cancer Center, Houston, TX

Role of FDG-PET/CT Surveillance for Patients with Classical Hodgkin’s Disease in First Complete Response: The Stanford University Experience

Lauren S Maeda, MD, Sandra J Horning, MD, Andrei H Iagaru, MD*, Frank I Lin, MD*, Richard T Hoppe, MD*, Saul A Rosenberg, MD* and Ranjana H Advani, MD

Stanford University, Stanford, CA

*signifies non-member of ASH